Advertisement

Palliative Care in Kidney Disease

  • Fliss E. M. MurtaghEmail author
Reference work entry

Abstract

This chapter first provides evidence about identifying which patients with kidney disease might need palliative or supportive care. Although care should be based on needs and not on prognosis, it is nevertheless important to consider palliative needs in the context of the number of weeks, months, or years which remain. What needs to be addressed only weeks from death is often very different – and more urgent – than what needs to be addressed if there are years ahead. For this reason, there is a comprehensive overview of evidence on survival, so that the context of care can be understood.

Then a more detailed examination of how to identify and manage common symptoms is included, although details of management may vary from country to country, according to local guidelines and availability of individual medicines. Pain, constipation, breathlessness, nausea, vomiting, itch, restless legs, and fatigue are all considered. The last days of life may sometimes prove challenging in terms of symptom management, yet it is important to provide best possible care at this time, so this stage of illness is considered in further detail.

Finally, team working, communication, and planning ahead – all crucial for effective and coordinated care – are then explored, to help facilitate best palliative and supportive care for this population.

References

  1. Azevedo Sao Leao FK, Kimura M, Jacobsen TM. The who analgesic ladder for Cancer pain control, twenty years of use: how much pain relief does one get from using it? Support Care Cancer. 2006;14(11):1086–93.CrossRefGoogle Scholar
  2. Barnes H, Mcdonald J, Smallwood N, Manser R. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016;3:Cd011008.PubMedGoogle Scholar
  3. Boger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med. 2006;20:S17–23.CrossRefGoogle Scholar
  4. Bonner A, Wellard S, Caltabiano M. The impact of fatigue on daily activity in people with chronic kidney disease. J Clin Nurs. 2010;19:3006–15.CrossRefGoogle Scholar
  5. Broadbent A, Khor K, Heaney A. Palliation and chronic renal failure: Opoid and other palliative medications – dosage guidelines. Prog Palliat Care. 2003;11:183–90.CrossRefGoogle Scholar
  6. Cheikh Hassan HI, Brennan F, Collett G, Josland EA, Brown MA. Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. J Pain Symptom Manag. 2015;49:782–9.CrossRefGoogle Scholar
  7. Cheng HWB, Chan KY, Lau HT, Man CW, Cheng SC, Lam C. Use of erythropoietin-stimulating agents (Esa) in patients with end-stage renal failure decided to forego Dialysis: palliative perspective. Am J Hosp Palliat Med. 2017;34:380–4.CrossRefGoogle Scholar
  8. Chin C, Booth S. Managing breathlessness: a palliative care approach. Postgrad Med J. 2016;92:393–400.CrossRefGoogle Scholar
  9. Cohen LM, Germain MJ. Measuring quality of dying in end-stage renal disease. Semin Dial. 2004;17:376–9.PubMedGoogle Scholar
  10. Cohen LM, Mccue JD, Germain M, Kjellstrand CM. Dialysis discontinuation. A ‘good’ death? Arch Intern Med. 1995;155:42–7.CrossRefGoogle Scholar
  11. Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet. 1996;31:410–22.CrossRefGoogle Scholar
  12. Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine For Pruritus. J Pain Symptom Manag. 2003;25:288–91.CrossRefGoogle Scholar
  13. Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis. 2003a;42:1239–47.CrossRefGoogle Scholar
  14. Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis. 2003b;42(6):1239–47.CrossRefGoogle Scholar
  15. Davison SN. The prevalence and management of pain in end-stage renal disease. J Palliat Med. 2007;10:1277–86.CrossRefGoogle Scholar
  16. Davison SN, Jassal SV. Supportive care: integration of patient-centered kidney care to manage symptoms and geriatric syndromes. Clin J Am Soc Nephrol. 2016;11:1882–91.CrossRefGoogle Scholar
  17. Davison SN, Torgunrud C. The creation of an advance care planning process for patients with Esrd. Am J Kidney Dis. 2007;49:27–36.CrossRefGoogle Scholar
  18. Davison SN, Jhangri GS, Johnson JA. Cross-sectional validity of a modified Edmonton symptom assessment system in Dialysis patients: a simple assessment of symptom burden. Kidney Int. 2006a;69:1621–5.CrossRefGoogle Scholar
  19. Davison SN, Jhangri GS, Johnson JA. Longitudinal validation of a modified Edmonton symptom assessment system (Esas) in Haemodialysis patients. Nephrol Dial Transplant. 2006b;21:3189–95.CrossRefGoogle Scholar
  20. Davison SN, Levin A, Moss AH, Jha V, Brown EA, Brennan F, Murtagh FE, Naicker S, Germain MJ, O'donoghue DJ, Morton RL, Obrador GT, Kidney Disease: Improving Global Outcomes. Executive summary of the Kdigo controversies conference on supportive care in chronic kidney disease: developing a roadmap to improving quality care. Kidney Int. 2015;88:447–59.CrossRefGoogle Scholar
  21. Dean M. Opioids in renal failure and Dialysis patients. J Pain Symptom Manag. 2004;28:497–504.CrossRefGoogle Scholar
  22. Dixon J, Matosevic T, Knapp M. The economic evidence for advance care planning: systematic review of evidence. Palliat Med. 2015;29(10):869–84.CrossRefGoogle Scholar
  23. Douglas CA. Palliative care for patients with advanced chronic kidney disease. J Roy Coll Phys Edinburgh. 2014;44:224–31.CrossRefGoogle Scholar
  24. Foote C, Kotwal S, Gallagher M, Cass A, Brown M, Jardine M. Survival outcomes of supportive care versus Dialysis therapies for elderly patients with end-stage kidney disease: a systematic review and meta-analysis. Nephrology. 2016;21:241–53.CrossRefGoogle Scholar
  25. Germain MJ, Cohen LM, Davison SN. Withholding and withdrawal from Dialysis: what we know about how our patients die. Semin Dial. 2007;20:195–9.CrossRefGoogle Scholar
  26. Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in Haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant. 2004;19:3137–9.CrossRefGoogle Scholar
  27. Houben CHM, Spruit MA, Groenen MTJ, Wouters EFM, Janssen DJA. Efficacy of advance care planning: a systematic review and meta-analysis. J Am Med Dir Assoc. 2014;15:477–89.CrossRefGoogle Scholar
  28. Hutchinson TA. Transitions in the lives of patients with end stage renal disease: a cause of suffering and an opportunity for healing. Palliat Med. 2005;19:270–7.CrossRefGoogle Scholar
  29. Jennings AL, Davies AN, Higgins JP, Broadley K. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev. 2001;4:Cd002066.Google Scholar
  30. Kane PM, Vinen K, Murtagh FE. Palliative care for advanced renal disease: a summary of the evidence and future direction. Palliat Med. 2013;27:817–21.CrossRefGoogle Scholar
  31. Karakan S, Sezer S, Ozdemir FN. Factors related to fatigue and subgroups of fatigue in patients with end-stage renal disease. Clin Nephrol. 2011;76:358–64.CrossRefGoogle Scholar
  32. Ke LS, Huang X, Hu WY, O’connor M, Lee S. Experiences and perspectives of older people regarding advance care planning: a meta-synthesis of qualitative studies. Palliat Med. 2017;31:394–405.CrossRefGoogle Scholar
  33. King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe Cancer pain and renal impairment: a European palliative care research collaborative opioid guidelines project. Palliat Med. 2011;25:525–52.CrossRefGoogle Scholar
  34. Lim CED, Ng RWC, Cheng NCL, Cigolini M, Kwok C, Brennan F. Advance care planning for Haemodialysis patients. Cochrane Database Syst Rev. 2016;2016(7):CD010737.Google Scholar
  35. Lovell N, Jones C, Baynes D, Dinning S, Vinen K, Murtagh FE. Understanding patterns and factors associated with place of death in patients with end-stage kidney disease: a retrospective cohort study. Palliat Med. 2017;31:283–8.CrossRefGoogle Scholar
  36. Lowney AC, Myles HT, Bristowe K, Lowney EL, Shepherd K, Murphy M, O'brien T, Casserly L, Mcquillan R, Plant WD, Conlon PJ, Vinen C, Eustace JA, Murtagh FE. Understanding what influences the health-related quality of life of hemodialysis patients: a collaborative study in England and Ireland. J Pain Symptom Manag. 2015;50:778–85.CrossRefGoogle Scholar
  37. Mercadante S, Arcuri E. Opioids and renal function. J Pain. 2004;5:2–19.CrossRefGoogle Scholar
  38. Morton RL, Snelling P, Webster AC, Rose J, Masterson R, Johnson DW, Howard K. Factors influencing patient choice of Dialysis versus conservative care to treat end-stage kidney disease. CMAJ. 2012;184:E277–83.CrossRefGoogle Scholar
  39. Murphy EL, Murtagh FE, Carey I, Sheerin NS. Understanding symptoms in patients with advanced chronic kidney disease managed without Dialysis: use of a short patient-completed assessment tool. Nephron Clin Pract. 2009;111:C74–80.CrossRefGoogle Scholar
  40. Murtagh FE, Higginson IJ. Death from renal failure eighty years on: how far have we come? J Palliat Med. 2007;10:1236–8.CrossRefGoogle Scholar
  41. Murtagh FEM, Weisbord S. Symptoms in renal disease: their epidemiology, assessment and management. In: Chambers EJ, Germain M, Brown E, editors. Supportive care for the renal patient. 2nd ed. Oxford: Oxford University Press; 2010.Google Scholar
  42. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007a;14:82–99.CrossRefGoogle Scholar
  43. Murtagh FE, Addington-Hall JM, Edmonds PM, Donohoe P, Carey I, Jenkins K, Higginson IJ. Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without Dialysis. J Palliat Med. 2007b;10:1266–76.CrossRefGoogle Scholar
  44. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without Dialysis: recommendations for practice. J Pain Palliat Care Pharmacother. 2007c;21:5–16.PubMedGoogle Scholar
  45. Murtagh FEM, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007d;14:82–99.CrossRefGoogle Scholar
  46. Murtagh FEM, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without Dialysis: recommendations for practice. J Pain Palliat Care Pharmacother. 2007e;21(2):5–16.PubMedGoogle Scholar
  47. Murtagh FE, Addington-Hall J, Edmonds P, Donohoe P, Carey I, Jenkins K, Higginson IJ. Symptoms in the month before death for stage 5 chronic kidney disease patients managed without Dialysis. J Pain Symptom Manag. 2010;40:342–52.CrossRefGoogle Scholar
  48. Murtagh F, Ramsenthaler C, Firth A, Groeneveld EI, Lovell N, Simon S, Denzel J, Bernhardt F, Schildmann E, Bausewein C, Higginson IJ. A brief, patient- and proxy-reported outcome measure for the adult palliative care population: validity and reliability of the integrated palliative outcome scale (Ipos) (in Eapc 2016: abstracts). Palliat Med. 2016a;30(6):NP11.Google Scholar
  49. Murtagh FE, Burns A, Moranne O, Morton RL, Naicker S. Supportive care: comprehensive conservative care in end-stage kidney disease. Clin J Am Soc Nephrol. 2016b;11:1909–14.CrossRefGoogle Scholar
  50. Murtagh FEM, Burns A, Moranne O, Morton RL, Naicker S. Supportive care: comprehensive conservative care in end-stage kidney disease. Clin J Am Soc Nephrol. 2016c;11:1909–14.CrossRefGoogle Scholar
  51. Okamoto I, Tonkin-Crine S, Rayner H, Murtagh FE, Farrington K, Caskey F, Tomson C, Loud F, Greenwood R, O'donoghue DJ, Roderick P. Conservative care for Esrd in the United Kingdom: a National Survey. Clin J Am Soc Nephrol. 2015;10:120–6.CrossRefGoogle Scholar
  52. Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, Hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8:287–313.CrossRefGoogle Scholar
  53. Richardson A. Holistic common assessment of supportive and palliative care needs for people with Cancer: report to the National Cancer Action Team. London: Kings College London; 2007.Google Scholar
  54. Roderick P, Rayner H, Tonkin-Crine S, Okamoto I, Eyles C, Leydon G, Santer M, Klein J, Yao GL, Murtagh F, Farrington K, Caskey F, Tomson C, Loud F, Murphy E, Elias R, Greenwood R, O'donoghue D. A National Study of Practice Patterns in Uk Renal Units in the use of Dialysis and Conservative Kidney Management to Treat People Aged 75 years and over with chronic kidney failure. Southampton: National Institute For Health Research; 2015.CrossRefGoogle Scholar
  55. Saini T, Murtagh FE, Dupont PJ, Mckinnon PM, Hatfield P, Saunders Y. Comparative pilot study of symptoms and quality of life in Cancer patients and patients with end stage renal disease. Palliat Med. 2006;20:631–6.CrossRefGoogle Scholar
  56. Schildmann EK, Groeneveld EI, Denzel J, Brown A, Bernhardt F, Bailey K, Guo P, Ramsenthaler C, Lovell N, Higginson IJ, Bausewein C, Murtagh FE. Discovering the hidden benefits of cognitive interviewing in two languages: the first phase of a validation study of the integrated palliative care outcome scale. Palliat Med. 2016;30:599–610.CrossRefGoogle Scholar
  57. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced Cancer, aids, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag. 2006;31(1):58–69.CrossRefGoogle Scholar
  58. Spathis A, Booth S, Moffat C, Hurst R, Ryan R, Chin C, Burkin J. The breathing, thinking, functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. NPJ Prim Care Respir Med. 2017;27:27.CrossRefGoogle Scholar
  59. Steinhauser KE, Christakis NA, Clipp EC, Mcneilly M, Mcintyre L, Tulsky JA. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA. 2000;284:2476–82.CrossRefGoogle Scholar
  60. Stevens LA, Viswanathan G, Weiner DE. Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance. Adv Chronic Kidney Dis. 2010;17:293–301.CrossRefGoogle Scholar
  61. Tonkin-Crine S, Okamoto I, Leydon GM, Murtagh FE, Farrington K, Caskey F, Rayner H, Roderick P. Understanding by older patients of Dialysis and conservative management for chronic kidney failure. Am J Kidney Dis. 2015;65:443–50.CrossRefGoogle Scholar
  62. Verberkt CA, Van Den Beuken-Van Everdingen MHJ, Schols J, Datla S, Dirksen CD, Johnson MJ, Van Kuijk SMJ, Wouters EFM, Janssen DJA. Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis. Eur Respir J. 2017;50(5).  https://doi.org/10.1183/13993003.01153-2017.CrossRefGoogle Scholar
  63. Walters AS, Lebrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C. Validation of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Med. 2003;4:121–32.CrossRefGoogle Scholar
  64. Wasylynuk BA, Davison SN. Palliative care in patients with advanced chronic kidney disease. CANNT J. 2015;25:28–32.PubMedGoogle Scholar
  65. Weathers E, O'caoimh R, Cornally N, Fitzgerald C, Kearns T, Coffey A, Daly E, O'sullivan R, Mcglade C, Molloy DW. Advance care planning: a systematic review of randomised controlled trials conducted with older adults. Maturitas. 2016;91:101–9.CrossRefGoogle Scholar
  66. Weisbord SD, Fried LF, Arnold RM, Rotondi AJ, Fine MJ, Levenson DJ, Switzer GE. Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis symptom index. J Pain Symptom Manag. 2004;27:226–40.CrossRefGoogle Scholar
  67. Weisbord SD, Fried L, Mor MK, Resnick AL, Unruh ML, Palevsky PM, Levenson DJ, Cooksey SH, Fine MJ, Kimmel PL, Arnold RM. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol. 2007;2:960–7.CrossRefGoogle Scholar
  68. Wilcock A, Charlesworth S, Twycross R, Waddington A, Worthington O, Murtagh FEM, Beavis J, King S, Mihalyo M, Kotlinska-Lemieszek A. Prescribing non-opioid drugs in end-stage kidney disease. J Pain Symptom Manag. 2017;54(5):776–87.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Wolfson Palliative Care Research Centre, Hull York Medical SchoolUniversity of HullHullUK

Personalised recommendations